OS Therapies to Present at The Spartan Capital Investor Conference
04 November 2024 - 1:00PM
Business Wire
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a
clinical-stage immunotherapy and Antibody Drug Conjugate (ADC)
biopharmaceutical company, today announced that Paul Romness, Chief
Executive Officer, and Gerald Commissiong, Chief Business Officer,
will present a corporate overview at The Spartan Capital Investor
Conference. The conference is being held on November 4, 2024 at the
Pierre Hotel in New York. The Company’s participation aligns with
our commitment to engage with industry leaders and investors.
Event:
The Spartan Capital Investor
Conference
Presentation Date:
Monday, November 4, 2024
Time:
4:45 PM ET
Mr. Romness and Mr. Commissiong will be available for one-on-one
meetings with registered investors of the conference.
The conference, organized in partnership with B2i Digital, a
leading digital marketing firm specializing in investor
communications, will feature presentations from over 30 carefully
selected companies. The event will include panel discussions,
one-on-one meetings, and networking sessions to maximize
interactions between investors and presenters.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the
identification, development and commercialization of treatments for
Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s
lead asset, is an immunotherapy leveraging the immune-stimulatory
effects of Listeria bacteria to initiate a strong immune response
targeting the HER2 protein. The Company has completed enrollment
for a 41-patient Phase 2b clinical trial of OST-HER2 in resected,
recurrent osteosarcoma, with results expected in the fourth quarter
of 2024. OST-HER2 has completed a Phase 1 clinical study primarily
in breast cancer patients, in addition to showing strong
preclinical efficacy data in various models of breast cancer.
OST-HER2 has been conditionally approved by the U.S. Department of
Agriculture for the treatment of canines with osteosarcoma. In
addition, OS Therapies is advancing its next generation Antibody
Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This
platform leverages the Company’s proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker.
For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
forward-looking statements within the meaning of the federal
securities laws. These forward-looking statements and terms such as
"anticipate," "expect," "intend," "may," "will," "should" or other
comparable terms involve risks and uncertainties because they
relate to events and depend on circumstances that will occur in the
future. Those statements include statements regarding the intent,
belief or current expectations of OS Therapies and members of its
management, as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, including those described
under the section entitled "Risk Factors" of our Registration
Statement on Form S-1 declared effective by the Securities and
Exchange Commission (the "SEC") on July 31, 2024, as well as any of
our periodic reports filed with the SEC, and that actual results
may differ materially from those indicated by such forward-looking
statements. Any forward-looking statements contained in this press
release speak only as of the date hereof, and, except as required
by the federal securities laws, OS Therapies specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104157136/en/
Corporate and Media Contact: Jack Doll 410-297-7793
Irpr@ostherapies.com
OS Therapies (AMEX:OSTX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
OS Therapies (AMEX:OSTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024